The collaboration will use Caprion’s CellCarta proteomics platform, which profiles the expression and identity of proteins detected in tissues and blood plasma, to support the discovery of biomarkers.
Caprion will identify pharmacodynamic biomarkers in plasma resulting from the administration of Berlex compounds in preclinical development.
“Caprion is looking forward to working with Berlex on their preclinical therapeutic candidates,” noted Dr Daniel Chelsky, chief scientific officer at Caprion. “We believe Caprion’s capabilities in the discovery of protein biomarkers will significantly impact our partner’s development efforts.”
Caprion is a drug discovery and development company focused initially in oncology and infectious disease. The company’s most advanced program will enter phase II clinical trials in the US for Shiga-toxin producing E coli infection in the third quarter of 2006.